Cancer Institute of New Jersey (CINJ), Hematologic Malignancies

Fingerprint Dive into the research topics where Cancer Institute of New Jersey (CINJ), Hematologic Malignancies is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.

Cyclin-Dependent Kinases Medicine & Life Sciences
Lymphoma Medicine & Life Sciences
B-Cell Chronic Lymphocytic Leukemia Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Non-Hodgkin's Lymphoma Medicine & Life Sciences
Hodgkin Disease Medicine & Life Sciences
Apoptosis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2020

Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma

Passero, F. C., Ravi, D., McDonald, J. T., Beheshti, A., David, K. A. & Evens, A. M., Jan 1 2020, In : British Journal of Haematology. 188, 2, p. 295-308 14 p.

Research output: Contribution to journalArticle

T-Cell Lymphoma
Hodgkin Disease
Apoptosis
Therapeutics
Jurkat Cells

Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma

Ravi, D., Sarkar, S., Purvey, S., Passero, F., Beheshti, A., Chen, Y., Mokhtar, M., David, K., Konry, T. & Evens, A. M., Jan 1 2019, (Accepted/In press) In : Leukemia.

Research output: Contribution to journalArticle

Cell- and Tissue-Based Therapy
Natural Killer Cells
Non-Hodgkin's Lymphoma
Lymphoma
Cell Line

Management of older Hodgkin lymphoma patients

Evens, A. M., Carter, J., Loh, K. P. & David, K. A., Dec 6 2019, In : Hematology (United States). 2019, 1, p. 233-242 10 p.

Research output: Contribution to journalArticle

Open Access
Hodgkin Disease
Dacarbazine
Bleomycin
Doxorubicin
Therapeutics